NY-UNIFRAX
7.4.2021 13:02:12 CEST | Business Wire | Press release
Unifrax , the leading manufacturer of high-performance specialty materials, today introduced a new, nano-structured alumina catalyst support technology for the transportation market – Eco-lytic™ by Unifrax . Housed within a vehicle’s catalytic converter, the Eco-lytic catalyst support fiber is designed to replace the existing catalytic converter or add to existing systems in order to enhance emission reduction, consume fewer precious metals and raw materials, and drive lower energy usage through vehicle weight reduction. The solution is designed to help prolong a cleaner engine life and enable vehicle manufacturers to meet increasingly stringent environmental, social, and governance (ESG) standards and regulations, while providing considerable cost savings as the market transitions to electric vehicles (EVs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005247/en/
Eco-lytic is currently in advanced testing with several global automakers. Preliminary results suggest the solution can reduce the mass of catalyst support media by up to 80 percent and lower platinum group metal loading by up to 40 percent compared to traditional systems. This results in increased efficiency due to faster light-off of catalytic performance. Unifrax will have commercial production capability on-line in late 2021.
“The transportation industry is going through an incredible transformation – vehicle manufacturers and regulators are focusing efforts on reducing greenhouse gas emissions and transitioning to electric or plug-in hybrid vehicles. This transition will not happen overnight, and the industry is in desperate need of nearer-term solutions to help bridge the sector’s transition to a greener footprint. Eco-lytic is that solution and the step change we need today,” said Chad Cannan, Senior Vice President of Research and Development, Unifrax. “Eco-lytic is poised to be a game changer for any conventional engine, large or small, mobile or stationary. Our product is designed to enhance emissions reductions, reduce the need for precious raw materials, extend cleaner engine lives and help drive a more sustainable carbon footprint through vehicle weight reduction.”
Eco-lytic’s flexible structure not only offers efficiency and cost savings benefits, it also provides transportation industry partners and manufacturers with unique packaging options. Unifrax has the ability to tailor the Eco-lytic product to meet the needs of individual partners through custom shapes and sizes to fit into locations where existing technologies cannot.
“Unifrax continues to pursue its mission to make the world a greener, cleaner, and safer place. We have been working to support the industry’s transition to EVs through a robust battery and technology solution portfolio that includes: our recently announced proprietary anode technology SiFab™, which drives significantly higher energy density in lithium ion batteries, our AGM separator materials, our large format lithium ion glass separators, our interstitial thermal runaway barriers, our battery compartment fire protection systems and now Eco-lytic,” said John Dandolph, President and CEO, Unifrax. “Eco-lytic provides an exciting bridge to reduce catalytic converter weights and costs, reduce the use of precious metals and raw materials, and minimize the environmental impact of conventional engines as the industry transitions to EVs. As such, Eco-lytic is a unique and proprietary solution which opens the door to a new age of emission control aligned with our mission at Unifrax.”
Building on Unifrax’s deep history of fiber-based technology and manufacturing, Eco-lytic is Unifrax’s first step into catalytic support. Unifrax, the inventor of specialty ceramic fibers, has a track record of 75+ years of developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, including electric vehicles, aerospace, and chemical processing.
Unifrax will be available during SAE’s WCX Digital Summit , April 13–15, 2021, to discuss the Eco-lytic technology with interested attendees. For more information on Eco-lytic, visit www.unifrax.com .
About Unifrax
Unifrax develops and manufactures high performance specialty materials used in advanced applications including high-temperature industrial insulation, electric vehicles, energy storage, filtration, and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn , and Facebook .
About Clearlake
Founded in 2006, Clearlake Capital Group, L.P. is an investment firm operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology, and consumer. Clearlake currently has approximately $35 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
